---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000029"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:41:13.541451+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B

## Summary
- Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.
- GAAP net loss $536M for 2024 due to $4.4B AIPR&D from Alpine Immune Sciences acquisition; non-GAAP net income $111M.
- FY2025 total revenue guidance $11.75-12.0B; combined non-GAAP R&D, AIPR&D, SG&A expenses guided at $4.9-5.0B.
- COO Stuart Arbuckle retiring July 1, 2025; CFO Charlie Wagner to add COO role, Duncan McKechnie to become CCO.
- JOURNAVX approved Jan 30, 2025 for moderate-to-severe acute pain; ALYFTREK approved Dec 20, 2024 for CF ages 6+.

## SEC filing metadata
- accession: 0000875320-25-000029
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/vrtx-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000029
- JSON: https://secwatch.observer/filing/0000875320-25-000029.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000029.txt

## Key facts
- Executive change
  Duncan J. McKechnie was appointed as Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA.
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm
- Executive change
  Charles F. Wagner, Jr. was appointed as Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm
- Executive change
  Stuart A. Arbuckle retired as Executive Vice President and Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
  - Action: retired
  - Role: Executive Vice President and Chief Operating Officer
  source text: On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.